3B BlackBio Dx Ltd

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd, formerly known as Kilpest India Limited, has published an advertisement clipping of its unaudited standalone and consolidated financial results for the quarter and half year ended 30th September, 2026, in Business Standard and Swadesh Jyoti Bhopal newspapers. The financial results were approved at the company's board meeting held on 13th November, 2026.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has announced its unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026. The company's revenue from operations was ₹5,645.17 crore for the half year, with a profit before tax of ₹4,258.82 crore. The company's earnings per equity share for the half year was ₹37.43.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has announced its unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026. The company's revenue from operations was ₹5,645.17 crore for the half year, with a profit before tax of ₹4,258.82 crore. The company's earnings per equity share for the half year was ₹37.43. The results have been reviewed by the Audit Committee and the Board of Directors has taken on record the Limited Review Reports of the Statutory Auditors.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has announced a newspaper publication regarding the loss of share certificates, as per SEBI circular no. HO/38/13/11(3)2025-MIRSD-POD/I/1102/2025.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has announced a special window for re-lodgement of transfer requests of physical shares, in accordance with SEBI Circular No. HO/38/13/11(2) 2026-MIRSD-POD/1/3750/2026, dated January 30, 2026.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has scheduled a board meeting on 13/11/2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and Half-Year ended on 30th September, 2026.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has submitted a certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the acceptance or rejection of dematerialized securities for the quarter ended 30th September, 2026.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has announced the re-appointment of Mrs. Mithla Dubey as a director, who retires by rotation and has offered herself for re-appointment. The re-appointment was approved by the company's 54th Annual General Meeting on September 29, 2026.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has announced the voting results of its 54th Annual General Meeting, where all resolutions were passed with significant promoter and public interest. The company declared a 50% dividend for the financial year 2025-26.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd (formerly Kilpest India Ltd) held its 54th AGM on 29th September 2026. The meeting was conducted through video conferencing and e-voting. The company declared a dividend of Rs. 5.00 per share for the year ended 31st March 2026. The AGM also approved the appointment of a new director and the ratification of the remuneration of the cost auditor. The company's financial performance for the year ended 31st March 2026 showed revenue from operations of Rs. 141.91 crores, profit before tax of Rs. 76.96 crores, and profit after tax of Rs. 59.92 crores.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has announced the closure of its trading window for directors, designated persons, and their immediate relatives from October 1, 2026, until 48 hours after the announcement of unaudited financial results for the quarter and half-year ending September 30, 2026.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd held an analyst/investor meet on September 16, 2026, where they interacted with Marcellus Investment Managers. The company reiterated information from their Q1-FY27 investor presentation, which was available in the public domain. No unpublished price-sensitive information was shared.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd held an analyst/investor meet on August 29, 2026, where they interacted with Param Capital. The company reiterated information shared through an investor presentation for Q1-FY27, which was available in the public domain. No unpublished price-sensitive information was disclosed.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has scheduled an analyst/investor meet on August 29th, 2026, to discuss the Q1-FY27 results, with a virtual conference call at 13:00 hrs IST.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has published its unaudited financial results for the quarter ended 30th June, 2026, in Business Standard and Swadesh Jyoti Bhopal newspapers. The results were approved at the company's board meeting held on 13th August 2026.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd releases Investor's Presentation for Q1 2026-27, highlighting revenue from operations of ₹3,349.08 lakhs, profit before tax of ₹1,321.95 lakhs, and profit after tax of ₹897.84 lakhs. The company also showcases its agrochemicals division's focus on government procurement and exports, with export sales of ₹58.99 lakhs in Q1 2026-27.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has announced unaudited financial results for the quarter ended 30th June, 2026, with revenue from operations at ₹2294.52 crores and profit for the period at ₹4,131.21 crores.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, which were reviewed by the Audit Committee. The company's agrochemical business is seasonal in nature and its performance can be impacted by weather conditions and cropping patterns.

3B BlackBio Dx Ltd

3B BlackBio Dx Ltd has scheduled a board meeting on 13/08/2026 to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended 30th June, 2026.